Fig 1.
Subject disposition flow diagram where n is number of subjects in each category.
Fig 2.
Median concentration-time profiles of darapladib following single and multiple dose administration over a period of 96 hours on linear-linear scale (A) and log- linear scale (B) truncated at 96 hours and (C) log-linear to the final observation.
Table 1.
Pharmacokinetic parameters of darapladib following single and multiple dose administration of darapladib enteric coated tablet 160 mg once daily.
Table 2.
Accumulation ratios for darapladib and SB-553253 for multiple relative to single dosing of darapladib.
Table 3.
Pharmacokinetic parameters of metabolite SB-553253 following single and multiple once daily dosing of darapladib enteric coated tablet 160 mg.
SB-553253 to Darapladib Cmax and AUC(0-τ) ratios are also presented.
Table 4.
Darapladib pharmacokinetic and pharmacodynamic parameters in healthy Chinese and Western subjects.
Fig 3.
Plasma darapladib concentration versus Lp-PLA2 activity v after multiple dose of darapladib.
Data points are indicated by symbols and the Emax relationship fitted is represented by the red line.
Table 5.
Emax model parameters for darapladib concentrations and associated LpPLA2 activity in healthy Chinese subjects.
Fig 4.
Darapladib single dose AUC(0-∞) relative to repeat dose AUC(0–24) in individual healthy Chinese and Western healthy subjects.